EBR:MDXH - Euronext Brussels - BE0974461940 - Common Stock - Currency: EUR
MDXH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. Both the profitability and financial health of MDXH have multiple concerns. While showing a medium growth rate, MDXH is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -51.61% | ||
ROE | -393.48% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 59.66% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.17 | ||
Debt/FCF | N/A | ||
Altman-Z | -3.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.43 | ||
Quick Ratio | 2.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
EBR:MDXH (12/15/2023, 7:00:00 PM)
3.02
-0.12 (-3.76%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.01 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5.1 | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -51.61% | ||
ROE | -393.48% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 59.66% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.17 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.43 | ||
Quick Ratio | 2.27 | ||
Altman-Z | -3.05 |